这项研究开创性地建立了基于双配体协同靶向的PCNA抑制剂设计新范式，其重要意义体现在三个方面：首先，提出的"构象熵补偿"机制为克服点突变耐药提供了全新思路，AL-3通过柔性连接链诱导的适应性构象变化，成功将突变体结合能恢复至野生型水平（ΔΔG=0.5 kcal/mol）；其次，整合网络药理学与多尺度计算的方法学框架，为多靶点药物开发提供了可推广的技术路线；最后 ...

编辑推荐：针对肝细胞癌 (HCC)增殖调控机制不明的科学问题，南昌大学团队揭示了NUB1通过负调控NEDD8-PCNA轴抑制肿瘤生长的全新机制。研究发现NUB1缺失通过上调NEDD8促进PCNA Lys¹⁶⁴位点NEDDylation，拮抗K48-linked多聚泛素化从而稳定PCNA蛋白，而NEDDylation抑制剂TAS4464可逆转该过程抑制HCC生长，为靶向 ...

The PCNA LI was 280.9 ± 226/1000 cells in end-of-treatment responders and 212.5 ± 216/1000 cells in end-of-treatment non-responders with no significant difference between both groups.

Hepatitis B Core Antigen Expression Pattern Reflects the Response to Anti-Viral Treatment ...

Review Article Published: 18 April 2013 Regulation of PCNA–protein interactions for genome stability Niels Mailand, Ian Gibbs-Seymour & Simon Bekker-Jensen Nature Reviews Molecular Cell Biology ...

MutLα (MLH1—PMS2) is a latent endonuclease that is activated in a mismatch-, MutSα-, proliferating cell nuclear antigen (PCNA)-, replication factor C (RFC)-, and ATP-dependent manner, with nuclease ...

BUFFALO, NY – June 4, 2025 – A new research paper was published in Volume 16 of Oncotarget on May 20, 2025, titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration ...

Researchers at City of Hope today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and ...